MA54327A - Inhibiteurs de kras g12c - Google Patents
Inhibiteurs de kras g12cInfo
- Publication number
- MA54327A MA54327A MA054327A MA54327A MA54327A MA 54327 A MA54327 A MA 54327A MA 054327 A MA054327 A MA 054327A MA 54327 A MA54327 A MA 54327A MA 54327 A MA54327 A MA 54327A
- Authority
- MA
- Morocco
- Prior art keywords
- kras
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 102200006538 rs121913530 Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946586P | 2019-12-11 | 2019-12-11 | |
| PCT/US2020/063272 WO2021118877A1 (fr) | 2019-12-11 | 2020-12-04 | Inhibiteurs de kras g12c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54327A true MA54327A (fr) | 2022-04-13 |
| MA54327B1 MA54327B1 (fr) | 2022-12-30 |
Family
ID=74106135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54327A MA54327B1 (fr) | 2019-12-11 | 2020-12-04 | Inhibiteurs de kras g12c |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US11731984B2 (fr) |
| EP (1) | EP3886991B1 (fr) |
| JP (1) | JP7023421B2 (fr) |
| KR (1) | KR102546592B1 (fr) |
| CN (2) | CN117820333A (fr) |
| AR (1) | AR120700A1 (fr) |
| AU (2) | AU2020402701B2 (fr) |
| BR (1) | BR112022009557A2 (fr) |
| CA (1) | CA3161162A1 (fr) |
| CL (1) | CL2022001513A1 (fr) |
| CO (1) | CO2022008091A2 (fr) |
| CR (1) | CR20220258A (fr) |
| DK (1) | DK3886991T3 (fr) |
| DO (1) | DOP2022000117A (fr) |
| EC (1) | ECSP22046699A (fr) |
| ES (1) | ES2929700T3 (fr) |
| HR (1) | HRP20221301T1 (fr) |
| HU (1) | HUE060684T2 (fr) |
| IL (2) | IL293394B2 (fr) |
| JO (1) | JOP20220142A1 (fr) |
| LT (1) | LT3886991T (fr) |
| MA (1) | MA54327B1 (fr) |
| MD (1) | MD3886991T2 (fr) |
| MX (1) | MX2022006986A (fr) |
| PE (1) | PE20230238A1 (fr) |
| PH (1) | PH12022551424A1 (fr) |
| PL (1) | PL3886991T3 (fr) |
| PT (1) | PT3886991T (fr) |
| RS (1) | RS63719B1 (fr) |
| SA (1) | SA522432955B1 (fr) |
| SI (1) | SI3886991T1 (fr) |
| TW (1) | TWI765448B (fr) |
| UA (1) | UA128806C2 (fr) |
| WO (1) | WO2021118877A1 (fr) |
| ZA (1) | ZA202205218B (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12065430B2 (en) | 2018-10-26 | 2024-08-20 | Taiho Pharmaceutical Co., Ltd. | Indazole compound or salt thereof |
| JOP20220101A1 (ar) | 2019-10-28 | 2023-01-30 | Merck Sharp & Dohme | مثبطات صغيرة الجزئ لطافر G12C لبروتين ساركوما جرذان Kirsten (KRAS) |
| WO2023205701A1 (fr) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Hétérocycles macrocycliques et leurs utilisations |
| TWI799871B (zh) * | 2020-05-27 | 2023-04-21 | 大陸商勁方醫藥科技(上海)有限公司 | 三環并環類化合物，其製法與醫藥上的用途 |
| PE20240493A1 (es) | 2020-06-02 | 2024-03-15 | Boehringer Ingelheim Int | 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cancer |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| MX2023003338A (es) | 2020-09-23 | 2023-06-14 | Erasca Inc | Piridonas y pirimidonas tricíclicas. |
| CN114437107A (zh) * | 2020-11-06 | 2022-05-06 | 江苏先声药业有限公司 | 哌嗪类化合物及其应用 |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| US20240293558A1 (en) | 2021-06-16 | 2024-09-05 | Erasca, Inc. | Kras inhibitor conjugates |
| JPWO2023008462A1 (fr) | 2021-07-27 | 2023-02-02 | ||
| AU2022371727A1 (en) | 2021-10-22 | 2024-05-02 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof |
| JP2024542692A (ja) * | 2021-12-01 | 2024-11-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 環化２－アミノ－３－シアノチオフェンを含むｋｒａ分解化合物 |
| WO2023099592A1 (fr) * | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | 2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer |
| WO2023099612A1 (fr) * | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | 2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer |
| PE20241356A1 (es) * | 2021-12-01 | 2024-07-03 | Boehringer Ingelheim Int | Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer |
| CN118574836A (zh) * | 2021-12-01 | 2024-08-30 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-胺基-3-氰基噻吩及衍生物 |
| TW202340202A (zh) | 2021-12-22 | 2023-10-16 | 美國加利福尼亞大學董事會 | Gtp酶抑制劑及其用途 |
| WO2023126822A1 (fr) | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Association d'un conjugué anticorps-médicament et d'un inhibiteur de rasg12c |
| EP4486345A1 (fr) * | 2022-03-04 | 2025-01-08 | Eli Lilly and Company | Procédé de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs de shp2 |
| EP4489738A1 (fr) | 2022-03-11 | 2025-01-15 | Kumquat Biosciences Inc. | Composés hétérocycliques et leurs utilisations |
| WO2023183585A1 (fr) | 2022-03-25 | 2023-09-28 | Eli Lilly And Company | Inhibiteurs de kras |
| CN119343334A (zh) | 2022-04-07 | 2025-01-21 | 伊莱利利公司 | 制造kras g12c抑制剂的方法 |
| EP4504209A1 (fr) | 2022-04-08 | 2025-02-12 | Eli Lilly and Company | Méthode de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs d'aurora a |
| US20240108618A1 (en) | 2022-06-30 | 2024-04-04 | Eli Lilly And Company | Kras g12c inhibitor dosing regimens |
| AU2023320565A1 (en) | 2022-08-05 | 2025-01-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2024040131A1 (fr) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Inhibiteurs de pyridopyrimidine kras |
| GB202212641D0 (en) | 2022-08-31 | 2022-10-12 | Jazz Pharmaceuticals Ireland Ltd | Novel compounds |
| WO2024081674A1 (fr) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Polythérapies pour le traitement du cancer |
| WO2024112654A1 (fr) | 2022-11-21 | 2024-05-30 | Treeline Biosciences, Inc. | Inhibiteurs de kras spirocycliques de dihydropyranopyrimidine |
| US20240343736A1 (en) | 2023-03-30 | 2024-10-17 | Eli Lilly And Company | Kras inhibitors |
| JP2024146897A (ja) | 2023-03-31 | 2024-10-15 | イーライ リリー アンド カンパニー | Ｋｒａｓ阻害剤 |
| WO2024243441A1 (fr) | 2023-05-24 | 2024-11-28 | Kumquat Biosciences Inc. | Composés hétérocycliques et leurs utilisations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008007661A1 (fr) * | 2006-07-11 | 2008-01-17 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique tricycique et son utilisation |
| TWI659021B (zh) * | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| EA033689B9 (ru) | 2013-10-10 | 2020-04-29 | Араксис Фарма Ллк | Ингибиторы g12c kras |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| MX2017012979A (es) | 2015-04-10 | 2017-11-28 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y metodos de uso de los mismos. |
| CN110603258A (zh) * | 2017-05-11 | 2019-12-20 | 阿斯利康(瑞典)有限公司 | 抑制g12c突变型ras蛋白的杂芳基化合物 |
| EP3678703A1 (fr) | 2017-09-07 | 2020-07-15 | Revolution Medicines, Inc. | Compositions d'inhibiteur de la shp2 et méthodes de traitement du cancer |
| CN111051306B (zh) * | 2017-09-08 | 2023-01-03 | 美国安进公司 | Kras g12c的抑制剂及其使用方法 |
| EP3710439B1 (fr) * | 2017-11-15 | 2023-02-15 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12c |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| AR116604A1 (es) | 2018-10-15 | 2021-05-26 | Lilly Co Eli | Inhibidores de kras g12c |
| SG11202109451TA (en) * | 2019-03-05 | 2021-09-29 | Astrazeneca Ab | Fused tricyclic compounds useful as anticancer agents |
| CN112390818B (zh) | 2019-08-12 | 2023-08-22 | 劲方医药科技(上海)有限公司 | 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途 |
-
2020
- 2020-12-04 CR CR20220258A patent/CR20220258A/es unknown
- 2020-12-04 MD MDE20210978T patent/MD3886991T2/ro unknown
- 2020-12-04 SI SI202030102T patent/SI3886991T1/sl unknown
- 2020-12-04 PH PH1/2022/551424A patent/PH12022551424A1/en unknown
- 2020-12-04 MX MX2022006986A patent/MX2022006986A/es unknown
- 2020-12-04 US US17/111,676 patent/US11731984B2/en active Active
- 2020-12-04 CA CA3161162A patent/CA3161162A1/fr active Pending
- 2020-12-04 RS RS20220956A patent/RS63719B1/sr unknown
- 2020-12-04 PE PE2022001047A patent/PE20230238A1/es unknown
- 2020-12-04 PT PT208340240T patent/PT3886991T/pt unknown
- 2020-12-04 EP EP20834024.0A patent/EP3886991B1/fr active Active
- 2020-12-04 LT LTEPPCT/US2020/063272T patent/LT3886991T/lt unknown
- 2020-12-04 TW TW109142894A patent/TWI765448B/zh active
- 2020-12-04 BR BR112022009557A patent/BR112022009557A2/pt active Search and Examination
- 2020-12-04 JO JOP/2022/0142A patent/JOP20220142A1/ar unknown
- 2020-12-04 IL IL293394A patent/IL293394B2/en unknown
- 2020-12-04 CN CN202311816497.XA patent/CN117820333A/zh active Pending
- 2020-12-04 HU HUE20834024A patent/HUE060684T2/hu unknown
- 2020-12-04 PL PL20834024.0T patent/PL3886991T3/pl unknown
- 2020-12-04 KR KR1020227019240A patent/KR102546592B1/ko active IP Right Grant
- 2020-12-04 MA MA54327A patent/MA54327B1/fr unknown
- 2020-12-04 AU AU2020402701A patent/AU2020402701B2/en active Active
- 2020-12-04 WO PCT/US2020/063272 patent/WO2021118877A1/fr active Application Filing
- 2020-12-04 HR HRP20221301TT patent/HRP20221301T1/hr unknown
- 2020-12-04 ES ES20834024T patent/ES2929700T3/es active Active
- 2020-12-04 DK DK20834024.0T patent/DK3886991T3/da active
- 2020-12-04 JP JP2021539866A patent/JP7023421B2/ja active Active
- 2020-12-04 UA UAA202201784A patent/UA128806C2/uk unknown
- 2020-12-04 CN CN202080085553.5A patent/CN114828964B/zh active Active
- 2020-12-09 AR ARP200103420A patent/AR120700A1/es unknown
-
2022
- 2022-05-11 ZA ZA2022/05218A patent/ZA202205218B/en unknown
- 2022-06-07 CO CONC2022/0008091A patent/CO2022008091A2/es unknown
- 2022-06-07 DO DO2022000117A patent/DOP2022000117A/es unknown
- 2022-06-08 CL CL2022001513A patent/CL2022001513A1/es unknown
- 2022-06-10 EC ECSENADI202246699A patent/ECSP22046699A/es unknown
- 2022-06-12 SA SA522432955A patent/SA522432955B1/ar unknown
-
2023
- 2023-06-28 US US18/343,326 patent/US20230339968A1/en active Pending
- 2023-07-17 IL IL304534A patent/IL304534A/en unknown
-
2024
- 2024-04-18 AU AU2024202573A patent/AU2024202573A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54327A (fr) | Inhibiteurs de kras g12c | |
| EP4087573A4 (fr) | Inhibiteurs de kras g12c | |
| EP3844151A4 (fr) | Inhibiteurs de kras g12c | |
| FR24C1026I1 (fr) | Inhibiteurs de kras g12c | |
| ZA202202362B (en) | Kras g12d inhibitors | |
| EP4182313A4 (fr) | Inhibiteurs de kras g12d | |
| EP4192585A4 (fr) | Inhibiteurs de kras g12d | |
| EP3790551A4 (fr) | Inhibiteurs de kras g12c | |
| MA54543A (fr) | Inhibiteurs de kif18a | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| EP3458445A4 (fr) | Inhibiteurs de kras g12c | |
| EP4240489A4 (fr) | Inhibiteurs de kras g12d | |
| IL312381A (en) | Kras g12c inhibitors | |
| EP3761992A4 (fr) | Inhibiteurs d'arginase | |
| MA52812A (fr) | Inhibiteurs de sarm1 | |
| EP3817736A4 (fr) | Inhibiteurs de pikfyve | |
| EP3938358A4 (fr) | Inhibiteurs de rad51 | |
| EP3801500A4 (fr) | Inhibiteurs de sarm1 | |
| MA52809A (fr) | Inhibiteurs de sarm1 | |
| EP3919491A4 (fr) | Inhibiteur d'akt | |
| MA51611A (fr) | Inhibiteurs de pi4kiiibêta | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| EP3976797A4 (fr) | Inhibiteurs anti-crispr | |
| EP4076665C0 (fr) | Inhibiteurs d' egfr | |
| EP3893881A4 (fr) | Inhibiteurs de pde9 au pyrazolopyrimidine cyclobutyle |